Details of the Drug Pharmacogenomic Perturbation Atlas

Sumatriptan Drug Info

Sumatran; Sumatriptanum; Sumax; GR 43175; GR 43175X; NP101; GR-43175; Imigran (TN); Imitrex (TN); KS-1116; Sumatriptanum [INN-Latin]; Sumatriptan (JAN/USP/INN); (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide

Therapeutic Class

Vasoconstrictor Agents

Cross-matching ID

PubChem CID

5358

ChEBI ID

CHEMBL128

CAS Number

CAS 103628-46-2

TTD Drug ID

D0Z6UC

VARIDT Drug ID

DR00331

ACDINA Drug ID

D00645

General Information of Drug (ID: DMVYXR8)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cell cycle	1.85	3.97e-2	110/124 (88.71%)	PCNA;CCNB1;CDC20;...
Herpes simplex virus 1 infection	-1.74	3.18e-2	165/498 (33.13%)	IFNGR1;IRAK4;MAP3K7;...
Natural killer cell mediated cytotoxicity	-1.74	3.24e-2	99/131 (75.57%)	IFNA4;FYN;RAC2;...
Complement and coagulation cascades	-1.75	3.31e-2	76/85 (89.41%)	C8G;ITGB2;MASP2;...
Type I diabetes mellitus	-1.75	3.72e-2	38/43 (88.37%)	HLA-DRB1;LTA;ICA1;...
Metabolism of xenobiotics by cytochrome P450	-1.76	3.70e-2	49/77 (63.64%)	CYP2F1;GSTM4;GSTK1;...
Retinol metabolism	-1.76	4.32e-2	41/68 (60.29%)	CYP2C8;ADH7;CYP2A6;...
Antigen processing and presentation	-1.78	4.53e-2	60/78 (76.92%)	KIR2DL3;KIR3DL1;TNF;...
Coronavirus disease	-1.81	3.45e-2	215/232 (92.67%)	RPLP2;C8G;RPL10;...
Neutrophil extracellular trap formation	-2.05	0.00e+0	101/189 (53.44%)	GP1BA;ITGB2;FPR3;...
IL-17 signaling pathway	-2.22	0.00e+0	84/94 (89.36%)	MAPK3;IL17RB;SRSF1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H